Balyasny Asset Management
KITE

Balyasny Asset Management’s Kite Pharma, Inc. KITE Stock Holding History

Balyasny Asset Management’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-95,000
Closed -$7.46M – 1940
2017
Q1 		$7.46M Sell
95,000
-115,000
-55% -$7.11M 0.03% 595
2016
Q4 		$9.42M Buy
+210,000
New +$10.3M 0.05% 494

Other funds holding KITE

CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Balyasny Asset Management's KITE Position: Q2 2017 in Review

Balyasny Asset Management sold out of Kite Pharma, Inc. (KITE) in Q2 2017, closing a stake of 3,900 shares — an estimated $318K sold.

Balyasny Asset Management first reported a position in KITE in Q2 2015 and held it in 4 quarters. The position peaked at $12.9M in Q3 2015. 220 funds tracked by Wall St. Rank hold KITE as of Q2 2017.

  • Balyasny Asset Management reported no remaining Kite Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
  • Balyasny Asset Management sold 3,900 Kite Pharma, Inc. shares in Q2 2017, an estimated $318K.
  • Balyasny Asset Management first reported a position in Kite Pharma, Inc. in Q2 2015 and held it in 4 quarters.
  • Balyasny Asset Management's Kite Pharma, Inc. position peaked at $12.9M in Q3 2015.
  • 220 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2017.

Based on Balyasny Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.